Nine Chapters Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Nine Chapters Capital Management’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-12,550	Closed	-$282K	–	1292
2015 Q2	$282K	Sell	12,550 -3,100	-20%	-$49K	0.02%	736
2015 Q1	$153K	Buy	15,650 +9,000	+135%	+$88.3K	0.01%	864
2014 Q4	$76K	Buy	6,650 +3,600	+118%	+$39.1K	0.01%	884
2014 Q3	$35K	Buy	3,050 +750	+33%	+$11.5K	﹤0.01%	963
2014 Q2	$45K	Buy	+2,300	New	+$40.6K	﹤0.01%	908

Other funds holding CASC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Nine Chapters Capital Management's CASC Position: Q3 2015 in Review

Nine Chapters Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2015, closing a stake of 12,550 shares — an estimated $282K sold.

Nine Chapters Capital Management first reported a position in CASC in Q2 2014 and held it in 5 quarters. The position peaked at $282K in Q2 2015. 93 funds tracked by Wall St. Rank hold CASC as of Q3 2015.

Nine Chapters Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
Nine Chapters Capital Management sold 12,550 Cascadian Therapeutics, Inc. shares in Q3 2015, an estimated $282K.
Nine Chapters Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2014 and held it in 5 quarters.
Nine Chapters Capital Management's Cascadian Therapeutics, Inc. position peaked at $282K in Q2 2015.
93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2015.

Based on Nine Chapters Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.